Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...

Pilatus Biosciences to Present New Data Highlighting Sex-Specific Efficacy of CD36-Targeting Antibody in Colorectal Cancer at ...

Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical company focused on the discovery and development of antibody therapeutics for oncology, inflammation, and autoimmune ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST) (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector ...

Researchers have developed an antibody that prevents the activation of the Dickkopf 1-Cytoskeleton-associated protein 4 (DKK1-CKAP4) pathway, which is important for tumor growth in several cancers, ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. Breast cancer frequently overexpresses the product of the ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses. Harnessing that ...

Preclinical data demonstrate enhanced efficacy of PLT012 in pMMR colorectal cancer models - Findings position CD36 as a promising metabolic checkpoint target in an underserved patient population DOVER ...

Osaka, Japan – Pancreatic cancer is an aggressive disease with few available treatments. Thankfully, researchers are hard at work to improve treatment options, and researchers from Japan have now ...